Current treatment status-Undergoing active treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment Posts on Medivizor

Surgery improves survival of colorectal cancer patients with lung metastasis

Posted by on Aug 17, 2018 in Colorectal cancer | 0 comments

In a nutshell This study investigated the outcomes of surgery to lung metastasis (LM; cancer spreads to the lungs) in patients with colorectal cancer. Researchers suggested that lung surgery increases the survival of these patients.   Some background Colorectal cancer is one of the major diseases seen in the US. LM appear in 5-15% of patients and...

Read More

Nilotinib versus imatinib in the treatment of CML

Posted by on Aug 13, 2018 in Leukemia | 0 comments

In a nutshell This study compared the effectiveness of nilotinib (Tasigna) with high-dose imatinib (Glivec) in patients with unresponsive chronic myeloid leukemia. Researchers concluded that nilotinib may be more effective as a long-term treatment for CML when compared to imatinib. Some background Chronic myeloid leukemia is a cancer of the bone...

Read More

Evaluating cardiovascular safety of carfilzomib in patients with relapsed or refractory multiple myeloma

Posted by on Aug 10, 2018 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the cardiovascular (heart and blood vessels) safety of carfilzomib (Kyprolis) in patients with relapsed or refractory (does not respond to treatment) multiple myeloma. This study concluded that the benefits of carfilzomib outweighed its risks. Some background Multiple myeloma is a type of cancer of the bone...

Read More

Maintenance rituximab plus bortezomib for mantle cell lymphoma

Posted by on Aug 1, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of rituximab (Rituxan) plus bortezomib (Velcade) for patients with mantle cell lymphoma after stem cell transplant. This study concluded that this combination is a safe and effective regimen in these patients. Some background The standard treatment for younger patients with mantle cell...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Does graft versus host disease affect relapse and survival rates after a stem cell transplant in childhood leukemia?

Posted by on Jul 13, 2018 in Leukemia | 0 comments

In a nutshell This study examined the effect of graft versus host disease on relapse rates in children with acute leukemia. This study concluded that graft versus host disease may protect against relapse, but they did not see an effect on survival. Some background One complication following an allogeneic stem cell transplant (transplant using donor...

Read More

The safety and effectiveness of treatment for elderly patients with acute myeloid leukemia

Posted by on Jul 11, 2018 in Leukemia | 0 comments

In a nutshell This study was a systematic review (looking at all available and relevant evidence) of the safety and effectiveness of different treatment options for elderly patients with acute myeloid leukemia (AML). The study found that azacitidine (Vidaza) was safe and more effective than intensive chemotherapy in these patients.   Some...

Read More